The Pharmaceutical Research and Manufacturers of America has eliminated 22 companies from its membership, or about 42%, as part of an effort to refocus its constituency on research-based biopharmaceutical firms.
Putting The 'Big' Back In PhRMA: New Membership Criteria Pares Ranks
PhRMA eliminates 42% of members in conjunction with new membership eligibility criteria stipulating minimum R&D investment levels.
More from Pricing Debate
More from Market Access
• By
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
As CMS administrator, Mehmet Oz will oversee the second cycle of Medicare drug price negotiations and Part D redesign issues, but will have experienced deputies to help.
• By
Newly published insights from a series of European Medicines Agency workshops can guide drug developers in designing development plans that meet the needs of both regulators and health technology assessment bodies.